Table 1.
FDA | EMA | AIFA | |
---|---|---|---|
Crizotinib | 2011 | 2012 a
2015 b |
2015 a 2017 b |
Ceritinib | 2014 c 2017 b |
2015 c 2017 b |
2017 c 2019 b |
Alectinib | 2016 c 2017 b |
2017 c 2017 b |
2018 c 2018 b |
Brigatinib | 2017 c 2020 b |
2018 c 2020 b |
2020 c 2020 b |
Lorlatinib | 2018 d
2021 b |
2019 d 2021 b |
2021 d |
a Previously treated with chemotherapy. b Front-line. c Post-crizotinib. d Post-ALK TKI. * Updated approvals by July 2023.